HealthTree Logo
search more_vert
close
person Sign In / Create Account
ASH 2023: Revumenib Combined With Decitabine/Cedazuridine And Venetoclax For Relapsed Or Refractory AML
Posted: Feb 07, 2024
ASH 2023: Revumenib Combined With Decitabine/Cedazuridine And Venetoclax For Relapsed Or Refractory AML image

A Phase 1/2 Study

Early results of a phase 1/2 study covering the use of revumenib (previously known as SNDX-5613) combined with decitabine/cedazuridine and venetoclax were presented at the ASH 2023 Conference held in December. This study (NCT05360160) was designed for children and adults, to treat the KMT2A and NPM1 gene mutations. Revumenib is a potent, selective inhibitor of KMT2A that has shown promising results for relapse or refractory AML. 

Revumenib

“Acute leukemia occurs when menin interacts with KMT2A, driving cell behavior during the immature phase, causing the cells’ failure to differentiate and become active. When this happens, the immature cells also take the space of healthy cells. Revumenib targets menin to disrupt the interaction that triggers this process, allowing the immature ones to become actually mature, healthy, functioning cells.”

Medication Administration

The dose escalation process of this study was the following:

  • Decitabine/cedazuridine was administered at 35 mg/100 mg daily on days 1-5.
  • Venetoclax was administered at 400mg daily on days 1-14.
  • Revumenib was administered at 113mg daily on days 1-28.
  • Maintenance revumenib is planned as a monotherapy after stem cell transplant.

Study Side Effects

The median age of this study was 27 years old (the range was 12-62 years old). Most patients had tried 2.5 prior treatment options. The most common side effects:

  • 63% experienced febrile neutropenia (a temperature over 101.3).
  • 63% experienced hyperphosphatemia (too much phosphate in your blood, which can cause kidney disease).
  • 63% experienced nausea.
  • 25% experienced AST/ALT elevation (may be a sign of liver problems).
  • 25% experienced decreased platelet count (may have trouble stopping bleeding).
  • 25% experienced decreased neutrophil count (a type of white blood cells that help fight infection).

Study Results

Bone marrow blasts decreased an average of 66% to 8%. And 100% of patients experienced morphologic remission (a disappearance of all cells with characteristics of cancer). Measurable residual disease was undetectable in 43% of patients. Several transitioned to a stem cell transplant and some are now in remission. This study is ongoing.

HealthTree CureHub

At HealthTree, we believe that patients are powerful and have an opportunity to contribute to research in an incredibly unique way. HealthTree Cure Hub empowers patients with the knowledge to actively participate in their health journeys while providing researchers with valuable insights from real-world experiences. HealthTree Cure Hub connects patients and researchers to not only accelerate the development of innovative treatments but also lays the foundation for a future where more educated patients and research leads to more effective and personalized cures. Visit HealthTree Cure Hub today to become an active participant in your care and contribute your unique experience to researchers to move closer to a cure. 

For assistance setting up your HealthTree Cure Hub account, reach out to our patient navigation team by phone: 1-800-709-1113 or email: support@healthtree.org

The author Lisa Foster

about the author
Lisa Foster

Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home. 

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Abbvie
Astellas Pharma
Servier

Follow Us

facebook instagram youtube